IQVIA prescription data through late April ↗ put Novo Nordisk's Wegovy ↗ pill at roughly 113,354 US prescriptions in its most recent reported week, up from 105,366 the week prior. Eli Lilly's Foundayo, the small-molecule oral GLP-1 launched on April 7, hit 5,612 prescriptions in its third week. The 20-to-1 volume ratio is the cleanest single read of the oral-GLP-1 race four months into Novo's lead and three weeks into Lilly's response.
The trajectories. Wegovy pill (oral semaglutide ↗ for obesity) launched in late January and has been climbing through retail channels at a steady weekly pace. The 113K weekly run rate is from US retail-channel data alone; NovoCare Pharmacy direct-to-consumer volumes are additional and not included in the IQVIA number. Foundayo (orforglipron) launched April 7 with a 1,390-script Week 1, climbed to 3,707 in Week 2, and now 5,612 in Week 3. The Foundayo trajectory is still accelerating week-on-week, and Lilly executives have asked analysts to wait 8 to 12 weeks for a clearer read on launch trajectory through pharmacy-fill noise. RBC and Deutsche Bank notes both echoed the wait-and-see frame.
The mechanism comparison. Wegovy pill is oral semaglutide, the same peptide molecule sold as injectable Wegovy and Ozempic ↗. Foundayo is orforglipron, a small-molecule GLP-1 receptor agonist that is the first GLP-1 pill that is not a peptide ↗. The clinical effect class is similar; the manufacturing economics, regulatory file, and dosing schedule are different. Foundayo has a once-daily oral pill profile that does not require the SNAC absorption enhancer and does not depend on stomach pH conditions. It should, in principle, have manufacturing and storage advantages over the peptide.
Why Novo is winning so far. Three factors look load-bearing. First, brand recognition. Novo started selling injectable Wegovy and Ozempic in 2017-2021, and prescribers know the name. Foundayo is a 2026 brand that prescribers have only recently encountered. Second, channel access. Novo has been building US distribution and managed-care contracts for semaglutide since the original injectable launches; the Wegovy pill rides that infrastructure. Lilly's Foundayo is launching into the same channels but starting fresh on managed-care formularies. Third, indication framing. Wegovy pill is approved specifically for obesity, the high-volume use case. Foundayo is approved for obesity as well, but the drug has been positioned by analysts and prescribers as the lower-efficacy option pending Phase 3 readouts that compare it directly with the dominant injectable franchise.
What 8 weeks decides. The Lilly request for 8 to 12 weeks of data before drawing conclusions is reasonable, and the Foundayo Week 4 through Week 12 run will determine whether the launch is on a Wegovy-pill-comparable trajectory delayed by 3 months or on a structurally lower trajectory that reflects either inferior commercial positioning or inferior product-market fit. The May 2 ozempic_pill piece ↗ noted that the Ozempic pill launch on May 4 (the same molecule as Wegovy pill but for T2D rather than obesity) would compete with Foundayo for prescriber mindshare. The IQVIA data say that competition is already going badly for Lilly on raw script volume, and the framing of "two products in active launch" understated how lopsided the race already was.
The commercial implication for the field. The original "oral GLP-1 finally has two products" framing the section ran two days ago needs an update. The two products are not commercially equivalent. Novo has a multiple-fold lead, brand recognition, and the same molecule (semaglutide) on both sides of the prescribing decision (T2D and obesity). Lilly's Foundayo is one product with one indication and a 3-month later start. The compounded-GLP-1 closure proposed by FDA on April 30 helps both companies, but it helps the company with the greater installed prescriber base more, and the gap is widening rather than narrowing.
The platform read. The GLP-1R ↗ target page on peptidemodel anchors the metabolic-disease corner. The platform's peptide focus continues to map cleanly onto Novo's portfolio (semaglutide is the molecule on every Novo GLP-1 product) and continues to leave Lilly's small-molecule GLP-1 territory (orforglipron) outside its design space. As the Lilly portfolio diversifies into small-molecule agonists, the natural peptide-vs-small-molecule split between the two companies' products becomes a structural feature of the corpus.
What May 11 reveals. Hims & Hers reports Q1 on May 11. The compounded-GLP-1 telehealth platform's Q1 print, plus management commentary on the FDA 503B closure and the changing landscape, will be the next piece of color on whether the branded oral GLP-1 race is reshaping the broader commercial landscape or whether compounded-and-telehealth supply has structural durability that the regulatory shift cannot dent. The TIDES USA peptide-therapeutics conference in Boston May 11-14 lands the same week and is the next industry venue for the broader oral-GLP-1 commercial discussion.